Quinidine for Brugada syndrome: Panacea or poison?

Brugada syndrome is associated with sudden cardiac death in young patients. Currently guidelines recommend the use of implantable cardioverter-defibrillator (ICD) in high-risk patients to prevent sudden cardiac death and adjunctive therapy with quinidine in those who have recurrent ventricular tachyarrhythmias to prevent electrical storm. Nevertheless, not all patients respond to quinidine, and management of those who do not respond to the therapy is frequently challenging. In this report, we presented the management of a difficult case of Brugada syndrome with recurrent ventricular tachyarrhythmias that did not respond to quinidine therapy.